RU2015117483A - Комбинации - Google Patents

Комбинации Download PDF

Info

Publication number
RU2015117483A
RU2015117483A RU2015117483A RU2015117483A RU2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A
Authority
RU
Russia
Prior art keywords
cancer
amino
amount
methyloxy
methylethyl
Prior art date
Application number
RU2015117483A
Other languages
English (en)
Russian (ru)
Inventor
Курт Роберт ОДЖЕР
Виджай Гопал Редди ПЕДДАРЕДДИГАРИ
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of RU2015117483A publication Critical patent/RU2015117483A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015117483A 2012-10-12 2013-10-10 Комбинации RU2015117483A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712869P 2012-10-12 2012-10-12
US61/712,869 2012-10-12
US201361833561P 2013-06-11 2013-06-11
US61/833,561 2013-06-11
PCT/US2013/064260 WO2014059095A1 (en) 2012-10-12 2013-10-10 Combinations

Publications (1)

Publication Number Publication Date
RU2015117483A true RU2015117483A (ru) 2016-12-10

Family

ID=50477878

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015117483A RU2015117483A (ru) 2012-10-12 2013-10-10 Комбинации

Country Status (11)

Country Link
US (1) US20160263116A1 (enExample)
EP (1) EP2906215A4 (enExample)
JP (1) JP2015533165A (enExample)
KR (1) KR20150067323A (enExample)
CN (1) CN104755079A (enExample)
AU (1) AU2013329199A1 (enExample)
BR (1) BR112015008155A2 (enExample)
CA (1) CA2888094A1 (enExample)
IN (1) IN2015DN02667A (enExample)
RU (1) RU2015117483A (enExample)
WO (1) WO2014059095A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
GB201510628D0 (en) * 2015-06-17 2015-07-29 Glaxosmithkline Ip No 2 Ltd Novel use
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2021253243B2 (en) * 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382906A (zh) * 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations

Also Published As

Publication number Publication date
JP2015533165A (ja) 2015-11-19
AU2013329199A1 (en) 2015-04-16
US20160263116A1 (en) 2016-09-15
CA2888094A1 (en) 2014-04-17
BR112015008155A2 (pt) 2017-07-04
KR20150067323A (ko) 2015-06-17
EP2906215A1 (en) 2015-08-19
IN2015DN02667A (enExample) 2015-09-04
CN104755079A (zh) 2015-07-01
EP2906215A4 (en) 2016-05-18
WO2014059095A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2008521928A5 (enExample)
JP2016503399A5 (enExample)
RU2015143610A (ru) Лечение катаплексии
JP2016528162A5 (enExample)
JP2011520977A5 (enExample)
JP2015529234A5 (enExample)
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
RU2015119218A (ru) Комбинация
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2014507412A5 (enExample)
RU2016141569A (ru) Комбинации
RU2015121424A (ru) Комбинированная терапия
JP2015536986A5 (enExample)
JP2017511360A5 (enExample)
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2014512356A5 (enExample)
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
HRP20120918T1 (hr) Aminopirazolski spoj
JP2015516988A5 (enExample)
JP2013541583A5 (enExample)
JP2013536243A5 (enExample)
JP2014512355A5 (enExample)
JP2019527740A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20161011